The unfolded protein response in neurodegenerative disorders - therapeutic modulation of the PERK pathway. by Hughes, Daniel & Mallucci, Giovanna
REVIEW ARTICLE
The unfolded protein response in neurodegenerative
disorders – therapeutic modulation of the PERK pathway
Daniel Hughes1 and Giovanna R. Mallucci1,2,3
1 MRC Toxicology Unit, Leicester, UK
2 Department of Clinical Neurosciences, University of Cambridge, UK
3 UK Dementia Research Institute, University of Cambridge, UK
Keywords
ER stress; neurodegeneration;
neuroprotection; PKR-like endoplasmic
reticulum kinase; unfolded protein response
Correspondence
D. Hughes, Medical Research Council
Toxicology Unit, Hodgkin Building, Lancaster
Road, Leicester LE1 9HN, UK
Tel: +44 1162525029
E-mail: dth32@mrc-tox.cam.ac.uk
(Received 20 December 2017, revised 25
January 2018, accepted 20 February 2018)
doi:10.1111/febs.14422
The unfolded protein response (UPR) is a highly conserved protein quality
control mechanism, activated in response to Endoplasmic Reticulum (ER)
stress. Signalling is mediated through three branches, PERK, IRE1, and
ATF6, respectively, that together provide a coordinated response that con-
tributes to overcoming disrupted proteostasis. PERK branch activation
predominantly causes a rapid reduction in global rates of translation, while
the IRE1 and ATF6 branch signalling induce a transcriptional response
resulting in expression of chaperones and components of the protein degra-
dation machinery. Protein misfolding neurodegenerative diseases show dis-
ruption of proteostasis as a biochemical feature. In the brains of animal
models of disease and in human post mortem tissue from many of these
disorders, markers of UPR induction, particularly, the PERK pathway can
be observed in close association with disease progression. Recent research
has revealed dysregulated UPR signalling to be a major pathogenic
mechanism in neurodegeneration, and that genetic and pharmacological
modulation of the PERK pathway results in potent neuroprotection.
Targeting aberrant UPR signalling is the focus of new therapeutic
strategies, which importantly could be beneficial across the broad spectrum
of neurodegenerative diseases.
Introduction
Neurodegenerative diseases vary in their clinical,
pathological and biochemical signatures. However, a
common feature of the protein misfolding neurodegen-
erative disorders is the misfolding and aggregation of
disease-specific proteins, associated with the death of
neurons. The disease-specific misfolded protein/s in the
brain include amyloid-beta (Ab) and hyperphosphory-
lated tau in Alzheimer’s disease (AD), a-synuclein in
Parkinson’s disease (PD), TDP-43, FUS or SOD1 in
amyotrophic lateral sclerosis (ALS) and the prion pro-
tein (PrP) in prion diseases. How these misfolded and
aggregated protein/s lead to extensive neuronal loss
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has been relatively unclear until recently, hence,
disease-modifying therapeutics remain frustratingly
elusive. An extensive body of research and many high-
profile drug trials have directly targeted these disease-
specific misfolded proteins, and while this approach is
supported by numerous preclinical studies, clinical effi-
cacy appears to be lacking. Ab plaques in particular
has been targeted in many trials for AD with little
clinical success [1–3], this is despite the relative efficacy
of the Ab reduction, forcing a re-examination of the
causes of neurodegenerative disease and whether other
pathogenic mechanisms may better explain the neuro-
toxicity observed.
As well as the numerous disease-specific features,
these disorders share many pathological similarities,
such as microglial activation, neuroinflammation and
disruption to proteostasis. An approach that targets a
common mechanism of neurodegeneration would be
beneficial in each specific disease that aberrant physio-
logical process is observed in, making a multifunc-
tional treatment an extremely attractive prospect. This
review will summarize recent evidence for the role of
one of these common processes – the dysregulation of
the unfolded protein response (UPR) due to protein
misfolding – in neurodegenerative disorders. The
review will also discuss current and future therapeutic
targeting of the UPR, focusing mainly on PERK and
its downstream effectors.
The Endoplasmic Reticulum and the
unfolded protein response (UPR)
The Endoplasmic Reticulum (ER) is a large dynamic
organelle with multiple functions including calcium
storage and lipid metabolism. Most importantly, the
ER is a major site of cellular protein synthesis. Secreted
proteins and integral membrane proteins are synthe-
sised and folded within the ER, as are some cytosolic
proteins [4]. Disruptions to the homeostasis of protein
folding lead to the accumulation of misfolded proteins
in the ER, resulting in the activation of three highly
conserved signal transduction pathways, which react to
and help cells recover from ER stress, these three sig-
nalling pathways are collectively known as the
unfolded protein response (UPR) [5–7]. The UPR is
the main quality control mechanism in the ER and
through this response the cell attempts to maintain or
recover proteostasis. However, if this is not possible,
for instance, if the ER stress is sustained and misfolded
protein cannot be refolded or degraded, the cell will
undergo apoptosis [5,7]. Three ER transmembrane pro-
teins transduce signals resulting from ER stress from
the ER lumen to the cytosol; inositol requiring enzyme
1 (IRE1), activating transcription factor 6 (ATF6) and
PKR-like endoplasmic reticulum kinase (PERK). One
master regulator, Binding immunoglobulin Protein
(BiP), binds to the ER luminal face of all three UPR
transducers under “normal” unstressed conditions. This
binding is believed to maintain PERK and IRE1 in
their monomeric inactive confirmation and masks a
golgi localization signal (GLS) on ATF6 [8]. The pres-
ence of misfolded protein/s in the ER facilitates BiP
dissociation from the three UPR effectors (Fig. 1),
allowing BiP to bind misfolded proteins directly. The
effects of this are twofold; firstly, BiP maintains the
misfolded polypeptide in a folding-competent state for
refolding by other chaperones such as GRP94 or for
ejection from the ER for degradation [8]. Secondly, BiP
dissociation causes activation of IRE1, ATF6 and
PERK and their associated downstream pathways.
There is also evidence that unfolded proteins can bind
the ER luminal regions of both PERK and IRE1
directly [6,9], this is believed to play a role in their acti-
vation and even protein folding [10].
IRE1
IRE1 is the most conserved ER stress sensor of the
UPR; it contains two enzymatic domains; a kinase
domain and an endonuclease domain, both located in
its cytoplasmic region [11–13]. Dissociation of BiP
from IRE1 leads to dimerization of IRE1 and trans-
phosphorylation by its kinase domain, which in turn
activates its endonuclease domain. The most studied
function of the endonuclease domain is cleavage of 26
base pairs from X-box binding protein 1 (XBP1)
mRNA (Fig. 1). This results in a frame shift in XBP1
mRNA leading to translation of a potent bZIP tran-
scription factor, XBP1s [12–14]. XBP1s binds endo-
plasmic reticulum stress elements (ERSE) in DNA and
promotes the induction of endoplasmic reticulum-
associated degradation (ERAD) components needed
for the degradation of misfolded protein by the 26S
proteasome. Molecular chaperones such as BiP and
GRP94 are also under the control of ERSEs. XBP1s
also indirectly regulates biogenesis and growth of the
ER by increasing the activity of phospholipid synthe-
sizing enzymes [11], increasing the folding capacity of
the ER in times of stress.
Another emerging cellular function of IRE1 is
control of regulated IRE1-dependent decay of mRNA
(RIDD) (Fig. 1). RIDD involves cleavage of ER-
associated mRNAs, however, in contrast to XBP1, the
mRNAs are degraded [14,15]. RIDD is thought to
decrease the abundance of incoming ER proteins
hence further reducing folding load in the ER [16].
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ATF6
ATF6 is found in an inactive form in the ER mem-
brane in complex with BiP. BiP binds to and blocks
two golgi localization sequences (GLS) found on the
luminal face of ATF6, preventing trafficking of ATF6
to the golgi leading to its retention in ER membrane.
Upon the dissociation of BiP, ATF6 is trafficked to
the golgi apparatus where it undergoes processing to
its active form. It is cleaved twice, first by luminal ser-
ine protease site one protease (S1P), then by
intramembrane metaloprotease site 2 protease (S2P)
[6,8,17]. The cleaved cytosolic fragment (nATF6) con-
tains a bZIP domain and translocates to the nucleus
to act as a transcription factor. Here, it binds the
ATF/cAMP response element and ERSE [8], upregu-
lating several chaperone proteins and prosurvival tar-
gets such as Herp, BiP and P58IPK [8].
PERK
In a similar manner to IRE1, dissociation of BiP from
PERK’s ER luminal face leads to dimerization, inter-
dimer trans-phosphorylation and activation of its
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Fig. 1. The unfolded protein response. The presence of misfolded proteins in the ER causes the dissociation of BiP from the three unfolded
protein response (UPR) sensors, protein kinase RNA (PKR)-like ER kinase (PERK), IRE1 and activating transcription factor 6 (ATF6), leading
to their activation. IRE1 activation results in splicing of X-box binding protein 1 (XBP1), spliced XBP1 (XBP1s) activates many UPR target
genes related to protein folding, lipid synthesis, protein translocation into the ER and ER-associated decay (ERAD). PERK phosphorylates
eIF2a, resulting in translational repression and the upregulation of a subset of UPR target genes including activating transcription factor 4
(ATF4) and the proapoptotic CHOP. ATF6 activation targets genes under the control of an endoplasmic stress response element (ERSE),
including molecular chaperones (such as BiP) and components of the ERAD system.
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cytosolic kinase domain [9,18]. Recent evidence also
suggests that the PERK protein can form a tetramer
which further increases its kinase activity [19]. In the
context of the UPR, PERK’s main cellular target is
eukaryotic Initiation Factor 2a (eIF2a) (Fig. 1).
PERK phosphorylates eIF2a at serine-51, resulting in
a temporary reduction in global protein synthesis
allowing the cell time to refold or degrade any
unfolded protein in the ER. A small subset of genes is
upregulated in response to phosphorylation of eIF2a
(Fig. 1), this is reliant on regulatory features found in
their 50 untranslated regions (50 UTR).
Translational control by phosphorylation of eIF2a
eIF2a forms the heterotrimeric eukaryotic initiation
factor 2 (eIF2) when complexed with eIF2b and eIF2c.
eIF2 is a essential constituent of ternary complex,
which is required for the initiation of translation of an
mRNA into a polypeptide [20]. eIF2 is bound by
either GDP or GTP. In its GTP bound state (eIF2-
GTP) eIF2 is able to bind to initiator methionine
tRNA (tRNAi-Met) to form the complete ternary
complex (eIF2-GTP-tRNAi-Met) [20–22]. Only when
ternary complex is fully formed can it associate with
the 40S ribosome to form the preinitiation complex
(PIC), without PIC assembly mRNAs cannot be trans-
lated.
The widely accepted rate-limiting factor of transla-
tional initiation and hence translation itself is the con-
version of eIF2-GDP into eIF2-GTP, which is under
control of the guanine nucleotide exchange factor
(GEF) eIF2B [23]. Phosphorylation of eIF2a at serine
51 (eIF2a-P) greatly increases the affinity of eIF2 to
eIF2B and this tight association potently inhibits
eIF2B’s GEF activity [20,23]. This causes an immedi-
ate and severe reduction in eIF2-GTP and hence tern-
ary complex, attenuating general translation. The
reduction is so severe due to the uneven stoichiometry
between eIF2 and eIF2B [24]; eIF2 outnumbers eIF2B
in the cytosol meaning a small increase in eIF2a-P can
sequester most, if not all, available eIF2B. Phosphory-
lation of eIF2a is a converging mechanism for reduc-
ing translation in response to a variety of stressors, it
is also phosphorylated by four eIF2a kinases, sig-
nalling through which is collectively termed the inte-
grated stress response [25,26]. These kinases are
PERK, protein kinase R (PKR) which responds to
viral infection, general control nonderepressible 2
(GCN2) which is activated by UV damage or amino
acid deprivation, and heme requiring eIF2a kinase,
which responds to iron deficiency.
Downstream of eIF2a-P signalling a select group of
proteins are upregulated, these include activating tran-
scription factor 4 (ATF4), proapoptotic C/EBP
Homologous protein (CHOP) and growth arrest and
DNA damage-inducible protein 34 kDa (GADD34).
Upregulation of ATF4 is the best studied of this sub-
set of proteins; it is able to escape the translational
block due to features found in its 50 UTR known as
upstream open reading frames (uORFs) [27]. In
response to eIF2a phosphorylation, ATF4 upregulates
a number of key genes including GADD34 and
CHOP. GADD34 is a regulatory subunit of protein
phosphatase 1 and targets it to dephosphorylate
eIF2a-P as part of a negative feedback loop, the func-
tion of which is to restore protein synthesis post ER
stress. CHOP is downstream of ATF4 and is itself a
transcription factor. It is produced in high quantity
after prolonged ER stress, promoting apoptosis as well
as ER stress-induced cytokine production in macro-
phages [28].
The UPR and neurodegeneration
The presence of unfolded protein in brains of patients
suffering with neurodegenerative diseases has been
increasingly documented over the last decade [29,30],
so it is perhaps unsurprising that recent research has
brought the UPR into focus as a converging patholog-
ical pathway and therapeutic target across the spec-
trum of these disorders.
UPR activation in human
neurodegenerative disease
Recently, histological evidence of UPR activation has
been reported in post mortem brain tissues from
patients with various different neurodegenerative dis-
eases, particularly, the detection of PERK-P and
eIF2a-P [31–34]. Upregulation of PERK branch UPR
markers in these disorders is associated temporally and
spatially with the accumulation of misfolded and
aggregated protein [33,35], the authors observed high
levels of P-PERK and eIF2a-P immunoreactivity in
the pons of progressive supranuclear palsy (PSP)
patients and in the hippocampus of Alzheimer’s suffer-
ers in comparison to nondiseased control brains. A
genome-wide association study searching for common
variants influencing the risk of PSP identified a single-
nucleotide polymorphism in intron 2 of the PERK
gene EIF2AK3 [36]. Patient-derived lymphoblastoid
cell lines with this mutation showed a stronger UPR
stress response than controls, suggesting that this
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variant may increase the risk of tauopathy via overac-
tivation of the PERK pathway of the UPR.
Other studies have shown UPR activation is an
early event in tauopathies, AD and also in PD [31,37–
39]. Immunoreactivity of ER stress markers P-PERK,
P-eIF2a and P-IRE1 was observed in pretangle hip-
pocampal neurons in several human cases of AD, AD
with Lewy body pathology and vascular dementia, and
this immunoreactivity was most abundant in neurons
with that contained ptau, the authors suggest that
chronic UPR activation is involved in both tau phos-
phorylation and AD pathogenesis from early disease
points. P-IRE1 correlates with AD disease pathology
and IRE1 also exerts control on cellular production of
Amyloid Precursor Protein (APP), cleavage of which
results in beta-amyloid [40]. P-PERK and eIF2a-P
immunoreactivity have been observed in dopaminergic
neurons of the substantia nigra in brain tissue of PD
patients that was not present in control brains [32]. P-
PERK was colocalized with a-Synuclein in disease
samples, which is often misfolded in disease-forming
aggregates. In addition to this, [34] found high levels
of UPR markers such as BiP and CHOP in motor
neurons taken from the spinal cords of sporadic ALS
patients. Taken together these studies suggest that
UPR activation could be a pathological mechanism
across the whole spectrum of neurodegenerative dis-
eases, occurring independently of the specific disease-
causing misfolded protein (Table 1).
Pathological observations of upregulation of the
UPR in human disease are very interesting, however,
it is difficult to establish a causal relationship from
these data alone. Hence, the above findings have been
used to inform studies in animals to attempt to further
elucidate the role of the UPR and its signalling com-
ponents in neurodegeneration.
UPR activation in animal models of
neurodegenerative disease
Numerous models of neurodegeneration have been
used to understand the pathogenic role of UPR sig-
nalling, with a wealth of data revealed from mouse
studies, assisted by experiments in Drosophila and
other rodent models. ER stress is a common feature in
animal models of neurodegeneration, recapitulating
the observations from human post mortem studies.
Raised levels of PERK-P and its downstream effectors
are observed in prion-infected mice [41,42] in rTg4510
mice, which overexpress human tau mutation harbour-
ing the P301L mutation associated with frontotempo-
ral dementia [43,44], in 5xFAD mice that express five
AD-linked mutations [45] as well as in mutant
SOD1-expressing mice [46]. Thus, both human post
mortem tissue and mouse models of neurodegenerative
diseases show a correlation between UPR activation,
particularly induction of the PERK branch, and neu-
ropathology.
Insight into the mechanistic relevance of these obser-
vations comes from recent work in prion-diseased and
frontotemporal dementia mice in particular. Studies
testing molecules targeting various parts of the PERK
pathway have shown promise in numerous disease
models.
Prion disease
Many mouse models of disease employ overexpression
of a disease-specific protein or mutant, which results in
variable phenotypic modelling of disease as well as
limited clinicopathological relevance (reviewed in refs.
[47,48]). Prion disease in mice, in contrast, recapitu-
lates all aspects of human prion disease from infectiv-
ity and biochemistry, to pathology and clinical signs.
Mouse prion disease, therefore, provides a model in
which the relationship between protein misfolding and
neuronal loss in disease can be studied directly. Mice
inoculated with prions follow a stereotypical and well-
studied disease time course. Tg37+/ mice overexpress
the mouse wild-type prion protein (PrP) approximately
threefold and succumb to prion disease 12 weeks after
inoculation with Rocky Mountain Laboratory prion-
infected brain homogenate. Prion-inoculated Tg37+/
mice display synapse loss at 7 weeks postinoculation
(wpi) in CA1 hippocampal neurons. PERK activation
and phosphorylation of its major target eIF2a are
observed from 9wpi, preceding neuronal loss from
10wpi [41]. Genetic intervention by lentivirally express-
ing human GADD34, the eIF2a-targeting component
of protein phosphatase 1, restores translation rates,
prevents behavioural deficits and the onset of clinical
signs as well as preventing neurodegeneration. Admin-
istration of salubrinal (a repressor of eIF2a dephos-
phorylation) increases eIF2a-P, which exacerbates
neurodegeneration and reduces survival time in these
mice. Importantly, these observations were also repli-
cated in prion-infected mice with wild-type levels of
prion protein, demonstrating that this is not a gene
dosage effect [41].
Frontotemporal dementia
The rTg4510 mouse model of frontotemporal dementia
(FTD) overexpresses human four-repeat P301L mutant
tau in the forebrain [49,50]. Tissue-specific expression
of the mutant tau is driven by crossing the tg4510 mice
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with a neuronal-specific promoter (CAMKIIa) tetracy-
cline-controlled transactivator-expressing mouse line,
meaning the mutant tau is neuronally expressed with
particularly high levels in the forebrain and hippocam-
pus. At around 2.5 months of age spatial memory is
impaired, when performance is examined using a Mor-
ris water maze. At 4 months of age tangle-like tau
inclusions can be seen in the cortex and can be
observed in the hippocampus from around 5.5 months
of age. This correlates with approximately 60% loss of
hippocampal neurons at 5.5 months [49]. Significant
motor impairment is present at 6 months followed by
cortical cell loss at 8.5 months and gross forebrain
atrophy at 10 months of age [50]. PERK-mediated
eIF2a phosphorylation and increased levels of the
downstream effector ATF4 is evident at 6 months of
age [44]. P-PERK, eIF2a-P as well as BiP are also sig-
nificantly increased in hippocampus and forebrain at
9 months of age [43].
Alzheimer’s disease
Genetic reduction in PERK in 5XFAD mice (an AD
model that expresses five mutations linked to familiar
AD) has been shown to rescue memory deficits and
cholinergic neurodegeneration [45]. Interestingly
PERK haploinsufficiency also prevented elevations in
beta-secretase 1 (BACE1), one of the secretases
involved in Ab production. This led to reduced Ab
levels and plaque burden. This is hypothesized to be
because BACE1 is upregulated during eIF2a phospho-
rylation in a similar manner to ATF4 [45]. Aberrant
phosphorylation of eIF2a has also been implicated in
memory loss, a key early clinical feature in AD as well
as many related neurodegenerative diseases. Long-term
synaptic plasticity and memory formation rely on
de novo protein synthesis so will be negatively affected
by sustained phosphorylation of eIF2a [51–53]. Down-
stream PERK pathway effector ATF4 is a repressor of
cAMP response element binding protein-mediated gene
expression, which is required for synaptic plasticity as
well as learning. In mice, reducing the phosphorylation
of eIF2a via the heterozygous expression of an eIF2a
phospho-null mutant enhances synaptic plasticity, spa-
tial learning and memory by lowering the threshold
for long-term potentiation (LTP) [54]. Conversely,
blocking the dephosphorylation of eIF2a impairs both
late-LTP and long-term memory in mice [54]. In a sim-
ilar study, genetic deletion of PERK and another
eIF2a kinase GCN2 improved synaptic plasticity and
spatial memory in a mouse model of AD [55].
Further evidence of UPR involvement in AD comes
from the APP/PS1 mouse model of AD. Genetic dele-
tion of PERK or GCN2 resulted in reduced eIF2a-P
which prevented impairments in synaptic plasticity
[55]. The reduction of eIF2a-P also prevented deficits
in spatial memory.
Amyotrophic lateral sclerosis (ALS)
A number of mouse models of ALS suggest a role for
the UPR in neuronal cell death, [46] studied three
models of SOD1 mutant transgenic mice in which
point mutations G93A or G85R were expressed at
varying levels. They found that ALS “vulnerable” neu-
rons were selectively prone to ER stress and that this
Table 1. UPR markers are observed in human neurodegenerative diseases as well as numerous mouse and fly models of disease.
Species Disease Markers Location Reference
Human AD P-PERK, eIF2a-P Hippocampus [33]
AD P-IRE1 Hippocampus CA1 [40]
AD, AD with lewy body
pathology, vascular dementia
P-PERK, eIF2a-P, P-IRE1 Hippocampus [31]
PD P-PERK, eIF2a-P Substantia Nigra [32]
PSP P-PERK, eIF2a-P Pons [33]
sALS Bip, CHOP Spinal cord [34]
sALS CHOP Spinal cord [57]
Mouse AD P-PERK, eIF2a-P, ATF4 Hippocampus [45,55]
ALS P-PERK, eIF2a-P, ATF4, GRP78, CHOP, XBP1s Spinal cord [46,56,58]
Charcot-Marie-Tooth 1B GRP78, CHOP, XBP1s Spinal cord [56]
FTD P-PERK, eIF2a-P, ATF4 Hippocampus, forebrain [43,44,80]
Prion P-PERK, eIF2a-P, ATF4, CHOP Hippocampus [41,42,70,80]
PD BiP, GRP94, PDI Spinal cord, brain stem [61]
Drosophila ALS eIF2a-P [59]
PD P-PERK, eIF2a-P, ATF4, CHOP [89]
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ER stress is among the earliest observable cellular
defects, which begins from a young age. ER stress
markers GRP78, XBP1s and CHOP were observed to
be elevated in the same G93A SOD1 mutant mice [56].
Levels of CHOP have been observed to be consider-
ably higher than nondisease controls in the spinal
cords of sporadic human ALS sufferers and mutant
SOD1 mice [57]. The elevated CHOP levels are primar-
ily found in motor neurons and microglia. SOD1
G85R mice that are haploinsufficent for PERK show
a significantly accelerated disease onset and reduced
survival [58], this was combined with earlier SOD1
aggregation suggesting PERK activation can have a
protective effect during ALS disease progression.
eIF2a-P is upregulated by toxic TDP43 aggregates
in drosophila and inhibition of PERK mitigates this
toxicity in the drosophila as well as cultured mam-
malian neurons [59]. Contrasting data show ATF4 can
play a protective role during ALS [60]. Although
ATF4 deficiency in mutant SOD1 G85R mice reduced
birth rate, mice that were born appeared more resis-
tant to ALS and had longer lifespans than mutant
mice expressing normal levels of ATF4 [60]. ATF4
knockdown increased aggregation of SOD1 at the end
stage of disease.
Parkinson’s disease (PD)
An a-Synuclein mouse model of PD in which the
A53T mutant of human a-Synuclein is placed under
the control of the PrP promoter also shows pathogenic
signalling by the ER is involved in neurodegeneration.
Disease onset in these mice, including axonal degenera-
tion and neuronal loss, coincided with the induction of
ER chaperones [61]. However, this upregulation was
not observed alongside increased phosphorylation of
eIF2a. Interestingly, salubrinal, which increases levels
of eIF2alpa phosphorylation, was protective in this
model of a-synucleinopathy, administration of salubri-
nal delayed disease onset and reduced accumulation of
a-synuclein in the ER [62]. A study in a rat PD model
in which ATF4 was introduced to the dopamine neu-
rons in the substantia nigra via an adenovirus showed
sustained expression of ATF4 resulted in severe nigra-
striatal degeneration [63]. ATF6 processing has also
been implicated in Parkinson’s pathology; cellular PD
models show a-synuclein inhibits processing of ATF6
and this results in an impaired ERAD function and
increased proapoptotic signalling [64]. This suggests
that some facets of UPR signalling could be protec-
tive.
ER stress is also implicated in Drosophila pink1 and
parkin mutant models of PD, [65] found that defective
mitochondria fuse with the ER via mitofusin bridges.
These bridges promote activation of the UPR and the
authors found reducing mitofusin contacts was neuro-
protective, they also show that inhibition of PERK
using small molecule GSK2606414 was also neuropro-
tective independent of the mitofusin bridges.
Huntington’s disease
ER stress is an early event in presymptomatic HD
mouse models and is evident in post mortem brains
of HD patients [66]. BiP and CHOP are both
observed as being upregulated in HD patient’s brains
in comparison with control brains [66]. Expanded
polyglutamine expansions, such as those found in dis-
ease-causing huntingtin (htt), are thought to result in
ER stress by interfering and inhibiting ERAD com-
ponents [67,68]. It has been shown recently that it is
the soluble form of htt that activates ER stress, this
occurs before formation of insoluble aggregates.
Suggesting it is the formation of small oligomers is
that is cytotoxic and that larger aggregates could
even be protective [69].
Therapeutic modulation of the PERK
pathway
As discussed above, genetic modulation of the PERK-
eIF2a pathway can prevent neurodegeneration in
prion-infected mice. In one study prion-infected
Tg37+/ mice were treated with GSK2606414, a
potent and bioavailable PERK inhibitor [70,71]
(Fig. 2). This compound effectively reduced levels of
P-PERK and eIF2a-P, resulting in protection from
hippocampal neuronal loss and preventing the emer-
gence of clinical signs of prion disease, even when
dosed after the emergence of early neurological disease
indicators. Deficits in burrowing, which is a hippocam-
pus-dependent measure of motivation, were reversed
by GSK2606414 as was spatial memory loss as mea-
sured by novel object recognition. This is particularly
exciting as both human and mouse prion disease are
particularly devastating when compared with other
neurodegenerative diseases, often only taking months
from diagnosis to death in humans [72], demonstrating
the efficacy of this approach. However, the drug was
particularly toxic to the pancreases of the mice likely
due to on-target effects of the compound. The pan-
creas is reliant on a robust ER stress response for reg-
ulation of the high levels of protein synthesis and
output, inhibition of which resulted in weight loss and
mild hyperglycaemia making systemic PERK inhibi-
tion unsuitable for therapeutic application.
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PERK inhibition using GSK2606414 is neuroprotec-
tive in two PD drosophila models, the compound pre-
vented neuronal death in pink1 and parkin mutant
flies [65]. TDP43 toxicity is ameliorated by
GSK2606414 in mutant flies as well as mammalian
neurons [59].
GSK2606414 was also profoundly neuroprotective
in the rTg4510 mouse model of frontotemporal demen-
tia [44]. Interestingly, the PERK inhibitor also seemed
to reduce the levels of disease-specific protein ptau,
possibly via a divergent mechanism of protection. This
is thought to be due to an interaction between activa-
tion of eIF2a kinases PERK and PKR and the activa-
tion of Glycogen Synthase Kinase 3b (GSK3b) [73,74]
which is a tau kinase linked to phosphorylation at dis-
ease relevant epitopes. PERK inhibition also inhibits
activation of GSK3b resulting in less pathogenic phos-
phorylation of tau [44]. Although the PERK inhibitor
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Fig. 2. Trazodone is neuroprotective in prion-infected and frontotemporal dementia mice, haemotoxylin and eosin staining shows reduced
neuronal loss in hippocampus CA1 as well as reduced ptau in neuronal ribbon. Modulation of the PERK-eIF2a pathway prevents
neurodegeneration. Disease-associated misfolded proteins activate protein kinase RNA (PKR)-like ER kinase (PERK) signalling in many
neurodegenerative diseases. Chronic translational repression is associated with neurodegeneration in several experimental models and
human post mortem tissue samples. Overexpression of GADD34 prevents neurodegeneration in prion-infected Tg37+/ mice by reducing
eIF2a-P. PERK inhibitor GSK2606414 prevents neurodegeneration in prion-infected Tg37+/ mice, rTg4510 frontotemporal dementia mice as
well as drosophila models of ALS and PD. Compounds promoting ternary complex formation (ISRIB, Dibenzoylmethane and Trazodone)
restore translation and are neuroprotective.
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is not suitable as a therapeutic because of the on-target
effects of pancreatic toxicity, this study acts as a proof
of principle that targeting of the PERK pathway may
hold promise in a wider variety of neurodegenerative
diseases. With a possibility of two mechanisms of
action, targeting both cause and effect of neurodegen-
eration, further study into safer PERK inhibition
strategies should be pursued.
A second compound, ISRIB (integrated stress
response inhibitor), which acts downstream of eIF2a
phosphorylation [75,76], has been used to successfully
delay neurodegeneration in prion-infected mice [42].
ISRIB binds to eIF2B stabilizing it in its dimeric form
[77] allowing it to act as a GEF even in the presence
of eIF2a-P. This results in a partial restoration of pro-
tein synthesis in ER-stressed conditions, ISRIB also
boosts memory in nonstressed conditions [77] as well
as reducing eIF2a-P-dependent stress granule assembly
[78]. Administration of ISRIB to prion-infected mice
resulted in an increase in survival and marked neuro-
protection of hippocampal neurons, reflected in an
improvement in various behavioural tests [42]. Impor-
tantly, the pancreases of the mice treated with ISRIB
were histologically indistinguishable from vehicle-
treated mice, suggesting that partial inhibition of the
PERK pathway and hence partial restoration of pro-
tein synthesis was enough to prevent neurodegenera-
tion without pancreatic toxicity. As ISRIB enhances
spatial and fear-associated learning in mice (Sidrauski
et al. [76]), it seems likely that preventing eIF2a-P-
mediated translational repression therapeutically will
also protect against early synaptic failure and memory
loss in neurodegenerative disorders, as well as later
neuronal cell death. Interestingly, ISRIB has also been
successfully used in mouse models of traumatic brain
injury, ISRIB reversed hippocampal-dependent cogni-
tive deficits in focal contusion and diffuse concussion
models [79]. Unfortunately, the insolubility of ISRIB
makes it unsuitable for translation into human
patients. This work, however, showed targeting the
PERK-eIF2a pathway partially was enough for neuro-
protection with minimal on-target side effects in a
plethora of conditions.
A further study aimed at repurposing drugs for use
in neurodegeneration identified two molecules. Both
partially restore protein synthesis rates during ER
stress [80]. Trazodone is a licensed antidepressant and
Dibenzoylmethane (DBM) is a curcumin analogue
which has been researched as having anticancer prop-
erties [81,82]. These compounds were effective in pre-
venting neurodegeneration in both prion-infected and
rTg4510 mice. Both Trazodone and DBM were neuro-
protective at clinically relevant doses [80] (Fig. 2).
Both compounds partially restored rates of translation
and Trazodone also decreased pathogenic ptau in
rTg4510 mice similarly to the PERK inhibitor (Fig. 2).
The compounds improved performance in a test of
spatial memory as well as a burrowing assay alongside
increasing survival. The mechanism for this remains
unclear but both compounds are thought to act down-
stream of eIF2a phosphorylation in a similar albeit
not identical way to ISRIB.
However, studies on the therapeutic modulation of
proteostasis, specifically the PERK pathway, have
yielded interesting results in different mouse models of
disease. Sephin 1, which prolongs translational repres-
sion, was shown to delay neurodegeneration in an
ALS model as well as a model of periphery neuropa-
thy Charcot-Marie-Tooth disease Type 1a [56].
Numerous studies use guanabenz, a similar compound
to sephin 1, and show a therapeutic benefit in ALS
disease models. Guanabenz extended lifespan, delayed
onset of disease symptoms and improved motor per-
formance in separate study using G93A SOD1 ALS
mice [83]. A different study using the same mutant
mice suggests that guanabenz significantly ameliorates
disease and increases survival as well as reducing accu-
mulation of mutant SOD1 [84]. In a contrasting study,
guanabenz is protective in SOD1 G93A mutant
expressing fibroblasts [85] but accelerates ALS-like dis-
ease progression in mice expressing the same mutant
SOD1. These studies appear contradictory to the
above studies mentioned previously that suggest restor-
ing translation as the key to neuroprotection. One
explanation for the difference may be whether the dis-
ease-specific protein can escape translational repression
by eIF2a-P, for instance, total levels of PrP are not
effected by increasing levels of eIF2a-P or by modula-
tion of the PERK pathway [41,70]. This means reduc-
ing translation as an adaptive mechanism will be
ineffectual, as PrPC will continue to be synthesized
and converted into PrPSc. Total levels of other disease-
causing proteins may be reduced by eIF2a-P meaning
less would become aggregated. Another possible expla-
nation may be related to the subcellular compartment
that the protein misfolds in. Protein aggregates in dif-
ferent cellular compartments may react differently to
modulation of proteostasis. Whether the protein can
be refolded/degraded may also be of relevance, pro-
teins that misfold inside the ER may be refolded as a
result of the chaperone increase downstream of UPR
activation, however, proteins like tau which misfold in
the cytosol may not. It is also possible that activation
of the UPR before misfolded protein aggregates
appear would be beneficial because of accumulation of
the various chaperones and components of protein
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degradation machinery downstream of ER stress. Fur-
ther research into this phenomenon is needed to know
how a particular disease will react to modulation of
proteostasis.
Discussion
It is clear that disease-modifying treatments for neu-
rodegenerative diseases are desperately needed. Recent
failures in clinical trials, particularly those aimed at
clearance of disease-specific aggregated protein such as
Ab [1–3] supports the pursuit of additional targets.
The wealth of data from various human neurodegener-
ative disease studies suggests that dysregulation of pro-
teostasis, and more specifically, aberrant signalling by
the UPR may be a common pathogenic mechanism in
neurodegeneration. However, the pathological signifi-
cance of this UPR activation in human disease
remains largely unknown: whether UPR signalling is a
protective mechanism or an active contributor to dis-
ease pathogenesis cannot be determined from neu-
ropathological observations alone. In animal disease
models modulation of the UPR has shown marked
early promise across many models of neurodegenera-
tion in vitro and in vivo. Targeting the UPR, and in
particular reducing activation of the PERK branch, is
an exciting prospect. It provides neuroprotection inde-
pendently of the disease-specific associated protein/s,
meaning a single therapeutic could be beneficial in
multiple disorders as shown by a growing number of
studies [41,42,44,59,65,70,80]. In specific instances,
increasing PERK-eIF2a signalling therapeutically
could be beneficial [56]. This apparent contradiction
nonetheless reflects the pivotal role of the UPR in neu-
rodegeneration. These studies use different disease
models and different proteins, which misfold in sepa-
rate cellular compartments. The treatment timings
across studies can also be influential. These are all fac-
tors that may affect study outcome.
The mechanism by which ER stress is activated may
also vary across diseases, for instance, misfolded pro-
teins in the ER as well as those that accumulate in the
cytosol seem to activate ER stress. Therefore, there
may be different mechanisms of ER stress activation
and these different mechanisms may respond differ-
ently to different therapeutic approaches. One such
divergent mechanism of UPR activation is starting to
be uncovered. ER-mitochondrial contacts, termed
mitochondria-associated ER membranes, are also of
increased interest in neurodegenerative diseases. The
interactions between the ER and mitochondria have
been observed as dysregulated in various disease mod-
els (thoroughly reviewed by [86]). Currently, little is
known about the effects of increasing/decreasing these
contacts. They may provide a mechanism for the acti-
vation of the UPR by mitochondrial dysfunction; a
novel observation that would greatly expand the
known UPR signalling cascades and provides a new
point of potential therapeutic intervention. Mitochon-
drial dysfunction is also observed in AD [87] and
interestingly, genetically or pharmacologically targeting
mitochondrial proteostasis increased fitness and lifes-
pan in GMC101 worms (a Caenorhabditis elegans
model of Ab1-42 toxicity [88]) as well as reducing amy-
loid aggregation in worms, cellular and transgenic
mouse models of AD [87].
Partial restoration of protein synthesis by targeting
up or downstream of eIF2a-P seems to be able to pre-
vent neurodegeneration in some but not all protein
misfolding neurodegenerative diseases without the pan-
creatic toxicity associated with systemic PERK inhibi-
tion. This is a very exciting concept and a huge step
forward in finding thus far elusive treatments for neu-
rodegeneration, to the point where a licensed drug has
successfully delayed neurodegeneration in different
mouse models. As there are multiple well-validated
points of the PERK pathway which could be targeted
therapeutically, the next challenge will be identifying
how best and at what stage of disease the pathway can
be modulated in human diseases.
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